Pluvicto
The Top Pharma List rankings are compiled from GlobalData’s pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. Listed below are the charts and positions for Pluvicto in this year’s pharmaceutical sales data alongside recent articles on PMLiVE featuring Pluvicto.
49
2030 Global forecast Ranking
Recent articles on PMLiVE featuring Pluvicto
The authorisation approximately triples the number of patients eligible to receive the therapy
Patients receiving Pluvicto plus best standard of care had a 38% reduction in the risk of death
The study met its primary endpoint of radiographic progression-free survival
The recommendation is for use in combination with androgen deprivation therapy
The approval for the treatment applies to England, Scotland and Wales
The treatment is the first FDA approved targeted radioligand therapy for mCRPC patients
Data provided by GlobalData
GlobalData provides trusted intelligence on the world’s largest industries including Pharmaceutical and Medical Devices. With over 2,000 in-house experts, our data-driven, technology-powered approach delivers gold-standard insights to help businesses navigate complex markets and predict future trends.
Our integrated platform empowers 4,000 of the world’s largest companies—including over 70% of FTSE 100 and 60% of Fortune 100 firms—to make timely, informed decisions through unique data, expert analysis, and innovative consulting solutions.
To find out more about how our research and insights can help you, please visit https://www.globaldata.com/who-we-are/why-globaldata/
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE’s Top Pharma List – Methodology